Expand FMED Menu
FMED MENU

FMED ETF Profile


Family: Fidelity
Name: Fidelity Disruptive Medicine ETF
Inception Date: 12-Jun-2023
Termination Date:
Investment Objective: The fund seeks long-term growth of capital. Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser's opinion, are engaged in robotic surgery, gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, and consumer wellness.
Prospectus
Top 10 Holdings
NET OTHER ASSETS -8.6293%
SECURITIES LENDING CF 31635A303 8.5985%
DANAHER CORP DHR 3.8093%
INTUITIVE SURGICAL INC ISRG 3.5696%
UCB SA UCB 3.3862%
COGENT BIOSCIENCES INC COGT 3.3192%
ALNYLAM PHARMACEUTICALS INC ALNY 3.2511%
LIFESTANCE HEALTH GROUP INC LFST 2.9919%
ARGENX SE SPONSORED ADR ARGX 2.7820%
BIO TECHNE CORP TECH 2.7291%
Top 10 Holdings Weight: 25.8%
Number of Holdings: 73
Shares Outstanding: 2,323,806
Total Net Assets: 57,642,010
NAV: 24.83
Net Expense Ratio: 0.50%
Asset Class: Equities (Stocks)
Developed or Emerging: Developed Market Funds
Country: US
Region:
Strategy:
Currency:
Commodity:
Sector: Healthcare
Industry:
Dividend Type:
Tax Exempt State:
Maturity Duration:
Market Cap: Broad Market / Multi-Cap
Credit Quality:
Mortgage Bond Types:
Bond Type:
Gov't Bond Types:
Reit Type:
Leverage Direction/Factor:
Is Currency Hedged: No
US or Ex-US: Domestic
Market Data Delayed 15 Minutes